RC
LAB icon

Rangeley Capital’s Standard BioTools LAB Stock Holding History

Rangeley Capital’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$46K Buy
+50,000
New +$60.5K 0.04% 132

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Rangeley Capital's LAB Position: Q1 2026 in Review

Rangeley Capital opened a new position in Standard BioTools (LAB) in Q1 2026: 50,000 shares worth $46K. The stake represents 0.04% of the portfolio and ranks #132 among its holdings.

155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

  • Rangeley Capital held 50,000 shares of Standard BioTools worth $46K as of Q1 2026.
  • Standard BioTools was a new Rangeley Capital position in Q1 2026.
  • Standard BioTools made up 0.04% of Rangeley Capital's portfolio in Q1 2026, its #132 holding.
  • 155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on Rangeley Capital's 13F filing for Q1 2026, filed 15 May 2026.